4201 - 4210 of 9033 Results
Title
Year
- Dysregulated miRNAs mark Parkinson’s disease progression2021RESTRICTEDTitle: Dysregulated miRNAs mark Parkinson’s disease progressionJournal Name: Nature AgingPublisher: Springer Science and Business Media LLCVol: 1Issue #: 3Start Page: 241End Page: 242Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1038/s43587-021-00046-2Citation Count: 3
- Quantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer’s disease2021RESTRICTEDTitle: Quantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer’s diseaseJournal Name: Nature AgingPublisher: Springer Science and Business Media LLCVol: 1Issue #: 6Start Page: 550End Page: 565Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1038/s43587-021-00071-1Citation Count: 51
- Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarker2022OPENTitle: Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarkerJournal Name: Nature Structural & Molecular BiologyPublisher: Springer Science and Business Media LLCVol: 29Issue #: 10Start Page: 978End Page: 989Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/s41594-022-00837-0Citation Count: 53
- Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial2021RESTRICTEDTitle: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trialJournal Name: Nature MedicinePublisher: Springer Science and Business Media LLCVol: 27Issue #: 8Start Page: 1451End Page: 1457Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1038/s41591-021-01455-xCitation Count: 136
- Aducanumab: look before leaping2021RESTRICTEDTitle: Aducanumab: look before leapingJournal Name: Nature MedicinePublisher: Springer Science and Business Media LLCVol: 27Issue #: 9Start Page: 1499End Page: 1499Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1038/s41591-021-01477-5Citation Count: 13
- Deep brain stimulation for obsessive–compulsive disorder: a crisis of access2022OPENTitle: Deep brain stimulation for obsessive–compulsive disorder: a crisis of accessJournal Name: Nature MedicinePublisher: Springer Science and Business Media LLCVol: 28Issue #: 8Start Page: 1529End Page: 1532Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/s41591-022-01879-zCitation Count: 78
- The protean roles of neuroinflammation in trauma, infections, autoimmunity and neurodegeneration2022RESTRICTEDTitle: The protean roles of neuroinflammation in trauma, infections, autoimmunity and neurodegenerationJournal Name: Seminars in ImmunologyPublisher: Elsevier BVVol: 61-64Issue #:Start Page: 101655End Page: 101655Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.smim.2022.101655Citation Count: 3
-
OPENTitle: An economic evaluation of the NightWatch for children with refractory epilepsy: Insight into the cost-effectiveness and cost-utilityJournal Name: Seizure: European Journal of EpilepsyPublisher: Elsevier BVVol: 101Issue #:Start Page: 156End Page: 161Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.seizure.2022.08.003Best OA location URL: http://www.seizure-journal.com/article/S1059131122001820/pdfCitation Count: 11
-
OPENTitle: Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imagingJournal Name: Seminars in Arthritis and RheumatismPublisher: Elsevier BVVol: 51Issue #: 5Start Page: 1125End Page: 1133Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.semarthrit.2021.08.004Best OA location URL: https://research.vumc.nl/en/publications/d083f460-428b-4cc9-b64c-8e646fc9a1c6Citation Count: 26
-
OPENTitle: Sarkosyl differentially solubilizes patient-derived alpha-synuclein fibril strainsJournal Name: Frontiers in Molecular BiosciencesPublisher: Frontiers Media SAVol: 10Issue #:Start Page: 1177556End Page: 1177556Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fmolb.2023.1177556Best OA location URL: https://doi.org/10.3389/fmolb.2023.1177556Citation Count: 8